HIGH-VOLUME · SEX-BALANCED

apremilast Side Effects

apremilast (also sold as Otezla) is HIGH-VOLUME in this FAERS book #45 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 66% of sex-coded reports are female (90,394 F / 46,320 M).

Data updated 2026-05-15

143,174
FAERS reports

FAERS voluntary reports, 2012 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

apremilast reporting skew - 66% of sex-coded reports are female (90,394 F / 46,320 M). Volume band HIGH-VOLUME #45 of 524 by FAERS report count; caseload MEGA-CASE.

High-report extract for apremilast (Otezla): 143,174 FAERS rows (2012-2025). Top named reactions: DIARRHOEA, NAUSEA, PSORIASIS. Outcome stamps DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2012–2025). Stamps MEGA-CASE · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.

DIARRHOEA leads 24,315 of 143,174 reports

DIARRHOEA
24,315
NAUSEA
21,927
PSORIASIS
20,247
HEADACHE
17,679
ABDOMINAL DISCOMFORT
8,065
PSORIATIC ARTHROPATHY
7,852
PAIN
6,595
RASH
6,479
VOMITING
6,346
ARTHRALGIA
6,226
FATIGUE
6,026
DEPRESSION
5,414
WEIGHT DECREASED
4,955
ABDOMINAL PAIN UPPER
4,760
PRODUCT DOSE OMISSION
4,594
MALAISE
4,477
PRURITUS
4,143

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 90,394 (66%)
Male 46,320 (34%)
Unknown 12

Age peak 45-64 (40,417 reports)

0-17 403 (1%)
18-44 19,476 (25%)
45-64 40,417 (52%)
65-74 12,401 (16%)
75+ 5,085 (7%)

FAERS filings rising toward 2025

12
13
14
15
16
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Death appears on 5,453 reports (3.8% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
SYSTEMIC LUPUS ERYTHEMATOSUS 1,750
TYPE 2 DIABETES MELLITUS 1,746
PSORIATIC ARTHROPATHY 1,731
GLOSSODYNIA 1,729
GENERAL PHYSICAL HEALTH DETERIORATION 1,721
RASH 1,714
SYNOVITIS 1,712
HYPOAESTHESIA 1,707
INFUSION RELATED REACTION 1,704
HYPERTENSION 1,703
RHEUMATOID ARTHRITIS 1,695
WOUND 1,677
HAND DEFORMITY 1,667
JOINT SWELLING 1,630
HEPATIC ENZYME INCREASED 1,621
FIBROMYALGIA 1,617
SWELLING 1,607
HELICOBACTER INFECTION 1,580
DUODENAL ULCER PERFORATION 1,578

Reactions in Hospitalization Reports

Hospitalization is lighter here (10,932). Reactions in that subset:

Reaction Reports
PSORIATIC ARTHROPATHY 2,086
RASH 2,053
FATIGUE 2,009
DIARRHOEA 1,929
RHEUMATOID ARTHRITIS 1,924
HEADACHE 1,920
NAUSEA 1,917
SYNOVITIS 1,894
PAIN 1,893
JOINT SWELLING 1,834
ARTHRALGIA 1,822
GENERAL PHYSICAL HEALTH DETERIORATION 1,798
VOMITING 1,795
INFUSION RELATED REACTION 1,779
HYPERTENSION 1,774
ARTHROPATHY 1,769
SYSTEMIC LUPUS ERYTHEMATOSUS 1,718
MALAISE 1,716
How to read apremilast FAERS figures (MEGA-CASE · DEATH-MARKED · HOSP-LIGHT)

FAERS holds 143,174 voluntary reports linked to apremilast (Otezla), 2012-2025. Death is listed on 5,453 (3.8%). Hospitalization appears on 10,932 (7.6%). Top co-reported indication: Psoriasis.

MEGA-CASE books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.

Read with apremilast

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-LIGHT stamps.